Blackstone Inc’s CRISPR Therapeutics CRSP Stock Holding History

Blackstone Inc’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-12,196	Closed	-$831K	–	184
2024 Q1	$831K	Hold	12,196	–	–	﹤0.01%	144
2023 Q4	$763K	Hold	12,196	–	–	﹤0.01%	122
2023 Q3	$554K	Hold	12,196	–	–	﹤0.01%	133
2023 Q2	$685K	Hold	12,196	–	–	﹤0.01%	132
2023 Q1	$552K	Hold	12,196	–	–	﹤0.01%	138
2022 Q4	$496K	Hold	12,196	–	–	﹤0.01%	130
2022 Q3	$797K	Hold	12,196	–	–	﹤0.01%	132
2022 Q2	$741K	Hold	12,196	–	–	﹤0.01%	160
2022 Q1	$766K	Hold	12,196	–	–	﹤0.01%	175
2021 Q4	$924K	Hold	12,196	–	–	﹤0.01%	328
2021 Q3	$1.36M	Buy	+12,196	New	+$1.53M	﹤0.01%	365

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Blackstone Inc's CRSP Position: Q2 2024 in Review

Blackstone Inc sold out of CRISPR Therapeutics (CRSP) in Q2 2024, closing a stake of 12,196 shares — an estimated $831K sold.

Blackstone Inc first reported a position in CRSP in Q3 2021 and held it in 11 quarters. The position peaked at $1.36M in Q3 2021. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

Blackstone Inc reported no remaining CRISPR Therapeutics position as of Q2 2024 after selling out during the quarter.
Blackstone Inc sold 12,196 CRISPR Therapeutics shares in Q2 2024, an estimated $831K.
Blackstone Inc first reported a position in CRISPR Therapeutics in Q3 2021 and held it in 11 quarters.
Blackstone Inc's CRISPR Therapeutics position peaked at $1.36M in Q3 2021.
449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on Blackstone Inc's 13F filing for Q2 2024, filed 14 Aug 2024.